1型糖尿病系统管理和效果评价-3C汕头亚组后续随访研究

注册号:

Registration number:

ChiCTR-OCH-14004686 

最近更新日期:

Date of Last Refreshed on:

2015-05-01 19:58:24 

注册时间:

Date of Registration:

2014-05-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

1型糖尿病系统管理和效果评价-3C汕头亚组后续随访研究

Public title:

Systemic disease-management programs application and evaluation in type 1 diabetic patients (A follow-up study of Shantou subgroup from 3C study)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

1型糖尿病系统管理和效果评价

Scientific title:

Systemic disease-management programs application and evaluation in type 1 diabetic patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林锟 

研究负责人:

林少达 

Applicant:

Lin Kun 

Study leader:

Lin Shaoda 

申请注册联系人电话:

Applicant telephone:

+86 13556422916

研究负责人电话:

Study leader's
telephone:

+86 13902778657

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jornbar@126.com

研究负责人电子邮件:

Study leader's E-mail:

linshaoda@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

汕头市长平路57号

研究负责人通讯地址:

汕头市长平路57号

Applicant address:

N0.57 Zhongshan Road, Shantou

Study leader's address:

N0.57 Zhongshan Road, Shantou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

汕头大学医学院第一附属医院内分泌科

Applicant's institution:

Department of Endocrinology, The First Af?liated Hospital of Shantou University Medical College

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

汕大医附一院伦审-科研-第028号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

汕头大学医学院第一附属医院伦理审查委员会

Name of the ethic committee:

The First Af?liated Hospital of Shantou University Medical College Ethics Review Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2014-02-13 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

汕头大学医学院第一附属医院内分泌科

Primary sponsor:

Department of Endocrinology, The First Affiliated Hospital of Shantou University Medical College

研究实施负责(组长)单位地址:

汕头市长平路57号

Primary sponsor's address:

N0.57 Zhongshan Road, Shantou

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

汕头大学医学院临床研究提升计划

Source(s) of funding:

Shantou University Medical College Clinical Research Enhancement Initiative

研究疾病:

1型糖尿病  

Target disease:

Type 1 diabetes mellitus

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

评估1型糖尿病系统管理体系的临床的(代谢控制、生活质量)、人文的(心理健康、自我管理)和经济的(卫生经济学)效应  

Objectives of Study:

To evaluate the clinical effect (glycemic control and quality of life), humanities effect (mental health and self-management) and economic effect (medical economics) of the systemic, integrated management model for T1DM

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)其他类型糖尿病
(2)其他严重伴随疾病(预期寿命小于1年)

Exclusion criteria:

1.other types of diabetes;
2.with other serious diseases(life expectancy less than 1 year).

研究实施时间:

Study execute time:

From 2014-06-01 00:00:00 To 2017-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2014-05-01 00:00:00 To 2014-05-31 00:00:00

干预措施:

Interventions:

组别:

case series

样本量:

250

Group:

case series

Sample size:

干预措施:

NA

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

汕头大学医学院第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Af?liated Hospital of Shantou University Medical College

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SDSCA量表评分

指标类型:

次要指标

Outcome:

The scores of SDSCA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DSRS量表评分

指标类型:

次要指标

Outcome:

The scores of DSRS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

EQ-5D量表评分

指标类型:

次要指标

Outcome:

The scores of EQ-5D

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 2 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

NA

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2014-05-23 00:00:00